Azura Ophthalmics Ltd.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Hadasit Medical Research Services and Development Ltd.

Zakhar Nudelman

Doron Friedman

Shimon Amselem

Omer Rafaeli

Yair Alster

Michael M Friedman

Doron Steinberg

Irith Gati

Silvio Gutkind

Rakefet Czerninski

Rakefet Czernimski

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said methods are performed by administering said composition comprising a selenium disulfide and an anhydrous semi-solid base. The stable anhydrous composition are substantially free of selenium disulfide agglomerates.

Selenium disulfide compositions for use in treating meibomian gland dysfunction

The present invention discloses a method of treating a head and neck cancer or preventing the development of pre-malignant lesions to this cancer, by administering locally to the oral cavity, a sustained release drug delivery system comprising a drug for the treatment of this cancer or for the prevention of said lesions, and at least one polymer, such that said system is attached to a surface in the oral cavity and remains attached thereto for at least 1 hour, accompanied by release of the drug and maintaining an effective therapeutic concentration thereof in the cavity, for at least 1 hour. Further are disclosed a sustained release drug delivery system and a liquid precursor varnish composition to this system.

Sustained release delivery systems for the prevention and treatment of head and neck cancers

Growing community of inventors

Netanya, Israel

Zakhar Nudelman